Drug Formulary Review Archives – January 1, 2006
January 1, 2006
View Issues
-
Applying evidence-based medicine to formulary decisions
Evidence-based is one term often heard at the ASHP meeting. In one presentation, Applying the principles of evidence-based medicine to formulary decisions: Development of an innovative tool to evaluate conflicting data, pharmacists at the University of Pittsburgh Medical Center (UPMC) described how they developed grading criteria to evaluate a body of literature, especially when it is conflicting. -
ASHP Foundation announces research results
At the midyear meeting, several researchers spoke about their Foundation-funded research projects. Here are preliminary details of two of them. -
ENH wins medication-use safety award
The ASHP Foundation has announced that Evanston (IL) Northwestern Healthcare (ENH) has been awarded the 2005 Award for Excellence in Medication-Use Safety. -
Research News
New research shows promising results in the use of mycophenolate mofetil (CellCept) to treat lupus without severe side effects associated with the current standard of care. -
News Briefs
Falsely elevated glucose readings, warns FDA; FDA warning: Adverse events with rFVIIa; ASHP provides reference to Consumer Reports guide; FDA approves updated labeling for Lexiva; Red cell aplasia, severe anemia linked to drug -
New FDA Approvals
Deferasirox is the first orally administered medication to be approved for this use. Treatment for iron overload, which can damage the heart and liver, had previously required daily prolonged drug infusions lasting eight to 12 hours. -
In The Pipeline
SGX Pharmaceuticals has announced that Troxatyl, an investigational drug in a pivotal Phase II/III clinical trial, has been granted fast track designation by the FDA for third-line treatment of acute myeloid leukemia in adults. -
Drug Criteria & Outcomes: Ramelteon (Rozerem) Formulary Evaluation
Ramelteon is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The FDA approval allows physicians to prescribe ramelteon for long-term use in adults.